<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39349494</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis.</ArticleTitle><Pagination><StartPage>22631</StartPage><MedlinePgn>22631</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22631</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-67945-3</ELocationID><Abstract><AbstractText>SpikoGen® COVID-19 vaccine is based on the spike protein extracellular domain of the ancestral Wuhan-Hu-1 strain modified by removal of the furin cleavage site and addition of stabilising mutations expressed as a recombinant protein in insect cells. It is formulated with Advax-CpG55.2™ adjuvant to ensure optimal immunogenicity. In this study, data from several SpikoGen® clinical trials was retrospectively analysed to assess for any effect of gender or age on seroconversion, neutralizing antibody levels or the incidence of adverse events. Following the 1st dose, older age was associated with a reduced rate of fatigue (RR 0.97, p &lt; 0.001), headache (RR 0.98, p = 0.034) and myalgia (RR 0.97, p=0.016), following the 2nd dose, the rate of fatigue (RR 0.98, p = 0.017) but following the 3rd dose no effect of age on adverse events was evident. Similarly, following the 1st dose, men reported a 19% lower incidence of fatigue, 36% lower incidence of headache and 28% lower incidence of myalgia when compared to women. Interestingly, there was no relationship between age or gender and serum neutralizing antibody levels, although after each vaccine dose there was a consistent trend to women having a higher seroconversion rate. There was no correlation between neutralizing antibody levels and adverse events. Unlike what is seen with mRNA vaccines, reactogenicity trended lower after each subsequent SpikoGen® dose. Overall, SpikoGen® exhibited positive immunogenicity and low reactogenicity, indicating that a low incidence of adverse events does not equate to poor immunogenicity. SpikoGen® remains a promising protein-based vaccine platform for COVID-19 protection.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anjidani</LastName><ForeName>Nassim</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Department, Orchid Pharmed Company, No. 12 Asad Abadi Street, 70th Alley, Tehran, 1969955311, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahpari</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Department, Orchid Pharmed Company, No. 12 Asad Abadi Street, 70th Alley, Tehran, 1969955311, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kafi</LastName><ForeName>Hamidreza</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Department, Orchid Pharmed Company, No. 12 Asad Abadi Street, 70th Alley, Tehran, 1969955311, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovsky</LastName><ForeName>Nikolai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vaxine Pty Ltd, Bedford Park, Adelaide, 5042, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barati</LastName><ForeName>Saghar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Department, Orchid Pharmed Company, No. 12 Asad Abadi Street, 70th Alley, Tehran, 1969955311, Iran. Barati.S@orchidpharmed.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063806" MajorTopicYN="N">Myalgia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>NA, RSH, HK, and SB are members of the Orchid Pharmed medical department which is in collaboration with CinnaGen company with respect to conducting clinical trials. NP is affiliated with Vaxine Pty Ltd.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349494</ArticleId><ArticleId IdType="pmc">PMC11442574</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-67945-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-67945-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li, L. et al. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine39, 5940–5953 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8328570</ArticleId><ArticleId IdType="pubmed">34420786</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, L. et al. Covax-19/Spikogen vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. Vaccine40(23), 3182–3192 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013662</ArticleId><ArticleId IdType="pubmed">35465982</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda-Okubo, Y. et al. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants. Vaccine41(48), 7116–7128 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873063</ArticleId><ArticleId IdType="pubmed">37863669</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda-Okubo, Y. et al. An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge. Vaccine41(32), 4710–4718 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10277844</ArticleId><ArticleId IdType="pubmed">37355452</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabarsi, P. et al. Safety and immunogenicity of SpikoGen, an advax-cpg55.2-adjuvanted sars-cov-2 spike protein vaccine: A phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. Clin. Microbiol. Infect.28, 1263–1271 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9012510</ArticleId><ArticleId IdType="pubmed">35436611</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabarsi, P. et al. Evaluating the efficacy and safety of SpikoGen, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: A phase 3 randomized placebo-controlled trial. Clin. Microbiol. Infect.29, 215–220 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9463077</ArticleId><ArticleId IdType="pubmed">36096430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabarsi, P. et al. Immunogenicity and safety of SpikoGen, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial. Immunology167, 340–353 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349507</ArticleId><ArticleId IdType="pubmed">35758850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabarsi, P. et al. Comparative immunogenicity and safety of SpikoGen, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial. Int. Immunopharmacol.127, 111436 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38147778</ArticleId></ArticleIdList></Reference><Reference><Citation>Coggins, S. A. et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. Open Forum Infect. Dis.9(1), ofab575 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8759445</ArticleId><ArticleId IdType="pubmed">35047649</ArticleId></ArticleIdList></Reference><Reference><Citation>Debes, A. K. et al. Association of vaccine type and prior SARS-CoV-2 infection with symptoms and antibody measurements following vaccination among health care workers. JAMA Intern. Med.181(12), 1660–1662 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8369424</ArticleId><ArticleId IdType="pubmed">34398173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauernfeind, S. et al. Association between adverse reactions and humoral immune response no longer detectable after BNT162b2 booster vaccination. Vaccines (Basel)10(10), 1608 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9611233</ArticleId><ArticleId IdType="pubmed">36298473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann, P. &amp; Curtis, N. Factors that influence the immune response to vaccination. Clin. Microbiol. Rev.32(2), e00084-18 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431125</ArticleId><ArticleId IdType="pubmed">30867162</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen, A. et al. COVID-19 vaccines: Considering sex differences in efficacy and safety. Contemp. Clin. Trials115, 106700 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824304</ArticleId><ArticleId IdType="pubmed">35149232</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggieri, A. et al. The influence of sex and gender on immunity, infection and vaccination. Ann. Ist. Super Sanita52(2), 198–204 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27364394</ArticleId></ArticleIdList></Reference><Reference><Citation>Oertelt-Prigione, S. The influence of sex and gender on the immune response. Autoimmun. Rev.11(6–7), A479–A485 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22155201</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, L. et al. Delta inulin adjuvant enhances plasmablast generation, expression of activation-induced cytidine deaminase and B-cell affinity maturation in human subjects receiving seasonal influenza vaccine. PLoS One10(7), e0132003 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503308</ArticleId><ArticleId IdType="pubmed">26177480</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassallo, A. et al. Sex and gender in COVID-19 vaccine research: Substantial evidence gaps remain. Front. Glob. Womens Health2, 761511 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8593988</ArticleId><ArticleId IdType="pubmed">34816252</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakawa, R. et al. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: A cross-sectional study. BMC Infect. Dis.22(1), 179 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8864597</ArticleId><ArticleId IdType="pubmed">35197017</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike, R. et al. Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination. Vaccines (Basel)10(3), 451 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950942</ArticleId><ArticleId IdType="pubmed">35335084</ArticleId></ArticleIdList></Reference><Reference><Citation>Green, M. S. et al. Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine. Vaccines (Basel)10(2), 233 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875740</ArticleId><ArticleId IdType="pubmed">35214694</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra-Estévez, D. et al. Self-reported adverse events within the seven days following the Spikevax® (Moderna) vaccination. Farm. Hosp.46(5), 301–307 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36183231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz-Prado, E. et al. A comparative analysis of a self-reported adverse events analysis after receiving one of the available SARS-CoV-2 vaccine schemes in Ecuador. Vaccines (Basel)10(7), 1047 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9323750</ArticleId><ArticleId IdType="pubmed">35891211</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, T. et al. Transcriptional differences for COVID-19 disease map genes between males and females indicate a different basal immunophenotype relevant to the disease. Genes (Basel)11(12), 1447 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7761414</ArticleId><ArticleId IdType="pubmed">33271804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen, H. &amp; Klein, S. L. Sex differences in immunity to viral infections. Front. Immunol.12, 720952 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8438138</ArticleId><ArticleId IdType="pubmed">34531867</ArticleId></ArticleIdList></Reference><Reference><Citation>Trigunaite, A., Dimo, J. &amp; Jørgensen, T. N. Suppressive effects of androgens on the immune system. Cell Immunol.294(2), 87–94 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25708485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ursin, R. L., Shapiro, J. R. &amp; Klein, S. L. Sex-biased immune responses following SARS-CoV-2 infection. Trends Microbiol.28(12), 952–954 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547628</ArticleId><ArticleId IdType="pubmed">33077340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackey, E. et al. Perinatal androgens organize sex differences in mast cells and attenuate anaphylaxis severity into adulthood. Proc. Natl. Acad. Sci. USA117(38), 23751–23761 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7519313</ArticleId><ArticleId IdType="pubmed">32917815</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolich-Žugich, J. The twilight of immunity: Emerging concepts in aging of the immune system. Nat. Immunol.19(1), 10–19 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29242543</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, I. et al. Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT162b2 mRNA COVID-19 vaccine. Vaccines (Basel)10(8), 1220 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9412348</ArticleId><ArticleId IdType="pubmed">36016109</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobashi, Y. et al. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. PLoS One17(6), e0269917 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9187057</ArticleId><ArticleId IdType="pubmed">35687563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, R. et al. Correlation of immunogenicity and reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 vaccines. mSphere7(2), e0091521 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044926</ArticleId><ArticleId IdType="pubmed">35285250</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi, M. et al. Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. PLoS One16(9), e0257668 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8452080</ArticleId><ArticleId IdType="pubmed">34543337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang, Y. H. et al. Can reactogenicity predict immunogenicity after COVID-19 vaccination?. Korean J. Intern. Med.36(6), 1486–1491 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8588964</ArticleId><ArticleId IdType="pubmed">34038996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebinger, J. E. et al. Symptomology following mRNA vaccination against SARS-CoV-2. Prev. Med.153, 106860 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8527734</ArticleId><ArticleId IdType="pubmed">34687733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>